Welcome to our dedicated page for Blade Air Mobility SEC filings (Ticker: BLDE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BLDE SEC filings page on Stock Titan provides access to the regulatory history of Blade Air Mobility, Inc., which has since changed its name to Strata Critical Medical, Inc. and now trades on Nasdaq under the symbol SRTA, as disclosed in a Form 8-K dated August 29, 2025. These filings document the company’s evolution from a technology-powered air mobility platform combining passenger and medical operations into a focused medical logistics business.
Among the key documents are multiple Current Reports on Form 8-K. One Form 8-K filed on August 5, 2025 furnishes a press release announcing financial results for the quarter ended June 30, 2025 under Item 2.02 (Results of Operations and Financial Condition). Another Form 8-K filed on August 1, 2025 describes an Equity Purchase Agreement under Item 1.01, outlining the terms under which a subsidiary of Joby Aviation agreed to acquire Blade’s Passenger business, including the structure of cash or stock consideration, earn-out provisions, and related non-compete and commercial arrangements.
A subsequent Form 8-K filed on August 29, 2025 reports the completion of the Passenger business sale, details the consideration received in Joby Aviation common stock and potential additional amounts, and explains the company’s name change to Strata Critical Medical, Inc. and ticker change to SRTA. That filing also discusses related agreements, such as a restrictive covenant agreement and a commercial agreement giving Joby a role in providing certain medical transport services, and notes amendments to the company’s charter and bylaws.
Later 8-K filings under the Strata Critical Medical name, such as those dated September 16, 2025 and November 10, 2025, describe material events including the acquisition of Keystone Perfusion Services, LLC and the release of quarterly financial results. Together, these filings show how the company has shifted toward mission critical logistics and medical services for hospitals and healthcare providers.
On Stock Titan, users can review these BLDE-linked filings with AI-powered summaries that highlight the main terms of material agreements, changes in corporate structure, and key financial disclosures. Real-time updates from EDGAR, along with structured access to Forms 8-K and other reports, help investors quickly understand how Blade’s historical regulatory record connects to the current Strata Critical Medical (SRTA) listing.
Strata Critical Medical reports that ARK Investment Management LLC and Catherine D. Wood beneficially own 7,455,284 shares of Common Stock, representing 8.57% of the class.
The filing allocates voting and dispositive authority: ARK holds sole voting and sole dispositive power over 7,455,284 shares while Catherine D. Wood holds shared voting and shared dispositive power over 7,455,284 shares. The Schedule 13G/A is signed and dated 04/30/2026.
Strata Critical Medical, Inc. CEO, Logistics Scott M. Wunsch reported equity compensation activity involving Class A common stock. On April 23, 2026, he acquired 57,172 shares at $0.0000 per share as a grant tied to performance-based restricted stock units that vested after meeting certified performance criteria.
On April 24, 2026, the company withheld 13,922 shares at $4.92 per share to cover tax obligations related to the PSU vesting, a non-market disposition. Following these transactions, he held 631,124 shares directly and 382,987 shares indirectly through a limited liability company he solely owns.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen reported compensation-related equity activity involving performance-based restricted stock units (PSUs). On April 23, he acquired 83,505 shares of Class A common stock at no cost upon certification that PSU performance criteria from a March 20, 2025 grant were met. On April 24, 40,960 shares were withheld by the company at $4.92 per share to cover tax withholding obligations tied to the PSU vesting. After these routine award and tax-withholding entries, Cohen directly holds 216,444 shares of Class A common stock.
Strata Critical Medical, Inc. director and Co-CEO/General Counsel Melissa M. Tomkiel reported equity compensation activity in Class A common stock. On April 23, 2026, she acquired 630,264 shares at $0.00 per share from the vesting of performance-based restricted stock units. On April 24, 2026, 321,750 shares were disposed of at $4.92 per share, representing shares withheld by the company to cover tax obligations related to that vesting, not an open-market sale. After these transactions, she directly held 1,922,504 shares of Class A common stock.
Strata Critical Medical, Inc. Co-CEO and CFO William A. Heyburn reported equity compensation activity involving the company’s Class A common stock. On April 23, 2026, he acquired 545,625 shares at $0.0000 per share upon vesting of performance-based restricted stock units granted on March 20, 2025, after the compensation committee certified that performance criteria were met.
On April 24, 2026, 301,731 shares were disposed of at $4.92 per share through shares withheld by the issuer to cover tax withholding obligations related to the PSU vesting, rather than an open-market sale. Following these transactions, Heyburn directly held 1,580,668 shares of Class A common stock.
Velibor Krstic filed an amended Schedule 13D showing a larger position in Strata Critical Medical’s public warrants and urging changes to their terms. He now beneficially owns 1,485,877 public warrants, or about 16.21% of the 9,166,644 public warrants outstanding as of April 15, 2026, plus 26,425 common shares.
Krstic invested approximately $25,291 of personal funds to build this warrant stake, including recent open‑market purchases at a weighted average price of about $0.017 per warrant. He advocates a mandatory exchange of warrants via amendment before their May 7, 2026 expiration, citing the company’s record 2025 Adjusted EBITDA of $14.1 million, a 2026 Adjusted EBITDA target of $29–$33 million, and over $110 million in total liquidity, including $61.2 million in cash and undrawn JPMorgan facilities.
Strata Critical Medical, Inc. calls a virtual 2026 annual stockholder meeting on May 28, 2026 at 9:00 a.m. Eastern to elect two Class II directors, ratify Deloitte & Touche LLP as auditor, and hold an advisory Say‑on‑Pay vote on 2025 executive compensation.
The company, formerly Blade Air Mobility, transformed in 2025 into a pure‑play medical logistics and services provider by selling its passenger business to Joby Aviation for approximately $76 million in Joby stock plus up to $45 million in holdbacks and earn‑outs, and acquiring Keystone Perfusion Services. It now operates Logistics and Clinical segments serving transplant and cardiovascular surgery customers.
Governance highlights include a classified Board, Co‑Chief Executive Officers William A. Heyburn and Melissa M. Tomkiel, and former CEO Robert Wiesenthal as Non‑Executive Chairman, with independent director Andrew Lauck expected to become Lead Independent Director after the meeting. The compensation program emphasizes pay for performance through cash bonuses tied mainly to Adjusted EBITDA and performance stock units.
Velibor Krstic filed an amended Schedule 13D reporting a significant warrant position in Strata Critical Medical, Inc. He beneficially owns 1,139,393 warrants, representing about 12.4% of the 9,166,644 public warrants outstanding as of the issuer’s latest annual report.
Krstic is a Swiss private investor who used approximately 19,380 dollars of personal funds to acquire these warrants, including 374,958 warrants bought on April 8, 2026 at a weighted average price of about 0.011 dollars per warrant. He also holds 26,425 shares of common stock, or roughly 0.03% of the 86,989,143 shares outstanding as of February 24, 2026.
He states that the warrants are significantly undervalued relative to the company’s fundamentals, citing Adjusted EBITDA of 14.1 million dollars and the integration of Keystone Perfusion. Krstic intends to monitor board and management decisions before the May 7, 2026 warrant expiration and may discuss potential actions such as a voluntary exchange offer or amendments to the warrant agreement, while noting no concrete plans under the specified regulatory categories.
Strata Critical Medical, Inc. investor Velibor Krstic filed a Schedule 13D after accumulating 764,435 public warrants to purchase Class A common stock. These warrants represent about 8.3% of the 9,166,644 public warrants outstanding, bought in Nasdaq open-market trades for roughly $15,231 of personal funds.
Krstic reports holding sole voting and dispositive power over all the warrants and states he acquired them for investment purposes, believing the SRTAW warrants are undervalued relative to the issuer’s fundamentals, including Adjusted EBITDA of $14.1 million and the integration of Keystone Perfusion. He indicates he may engage with the board, management, sponsor KSL Capital Partners, and other holders before the warrants’ May 7, 2026 expiration, potentially discussing actions such as a voluntary exchange offer or amendments to the Warrant Agreement.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen reported routine share dispositions related to tax withholding on vested restricted stock units. On September 4, 2025 and September 10, 2025, the issuer withheld a total of 9,190 shares of Class A common stock to satisfy tax obligations. After these withholdings, Cohen directly owns 94,570 shares. This amended filing corrects an earlier Form 4 that had overstated his direct beneficial ownership by 5,483 shares due to an omitted tax-withholding entry.